500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.
Press release | 2021-03-24
Dicot initiates first studies in disease animal models
The potency drug developer Dicot has for the first time initiated studies in animals with erectile dysfunction. In earlier studies, the company's drug candidate has only been tested on healthy animals. The new studies are an important step in gaining approval for clinical trials in humans.
Read More >
Pharmaceutical Project
The aim of this year's development work is to prepare LIB-01 for clinical studies next year.
Read More >Market
Premature ejaculation is an immature market that is expected to grow 8% over the next five-year period.
Read More >